Myocardial infarction, commonly known as a heart attack, is considered part of a spectrum referred to as acute coronary syndrome (ACS). Interruption of the blood supply to part of the heart leads to death or necrosis of myocardial cells when myocardial ischemia exceeds a critical threshold and overwhelms myocardial cellular repair mechanisms designed to maintain normal heart physiology.
Preclinical services offered
- Drug screening in in vivo (rat, mouse), in vitro and ex vivo models
- Evaluation of compounds effects on ventricular remodeling and dysfunction
- Evaluation of cardio-protective effects
- Combined disease models: myocardial infarction with risk factors and co-morbidities such as hyperlipidemia obesity and diabetes
View our factsheet by clicking on the document on the right.
In vivo models
- Myocardial infarction (rat, mouse) by the permanent ligation of the left anterior descending artery (LAD).
This surgical procedure imitates the pathophysiological aspects occurring in infarction-related myocardial ischemia.
- Ischemia reperfusion (rat and mouse) also referred to as acute myocardial infarction is based on the temporary occlusion of the LAD.
This model is commonly used to mimic human ventricular remodeling leading to heart failure with similarities to that observed in humans who sustain a myocardial infarction, survive and then subsequently develops heart failure.
Ex vivo / vitro assays
- Langendorff heart model
- Isolated cardiomyocytes
We propose a wide range of techniques to deliver key end-points: Echocardiography, Electrocardiogram, Millar probes, Telemetry, Histomorphology, Anatomopathology, Myocyte Calcium and Contractility Recording System, Biochemistry and Molecular Biology.
All of our studies are designed following our clients’ requests, please contact us for more information.